Organon & Lilly Expand Migraine Commercialization Agreement to 11 Additional Markets
JERSEY CITY, N.J. -- Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, announced it has expanded its agreement with Eli Lilly and Company (Lilly) to become the sole distributor and promoter for the migraine medicine Emgality® (galcanezumab) in the following additional markets: Canada, Colombia, Israel, South Korea, Kuwait, Mexico, Qatar, Saudi Arabia, Taiwan, Turkey and the United Arab Emirates. This expanded partnership builds on Organon’s role as sole distributor and promoter of Emgality in Europe since February 2024. Read More
Organon & Lilly Expand Migraine Commercialization Agreement to 11 Additional Markets
Organon & Lilly Expand Migraine Commercialization Agreement to 11 Additional Markets
Organon & Lilly Expand Migraine Commercialization Agreement to 11 Additional Markets
Organon & Lilly Expand Migraine Commercialization Agreement to 11 Additional Markets
Organon & Lilly Expand Migraine Commercialization Agreement to 11 Additional Markets
Ads Links by Easy Branches
Play online games for free at games.easybranches.com
Guest Post Services www.easybranches.com/contribute
Play online games for free at games.easybranches.com
Guest Post Services www.easybranches.com/contribute